Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Oncology Based In-Vivo CRO Market Expected To Grow In Terms Of Size?

The market size for oncology-oriented in-vivo cro has experienced significant growth in the recent past. It is projected to rise from $1.39 billion in 2024 to $1.5 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.7%. This growth over the historic period is largely due to an intensified attention on oncology treatments, an increase in cancer cases, a move towards personalized medicine, expansion in the pharmaceutical industry, and demand for specific targeted therapies.

The market size for in-vivo contract research organizations (CRO) focusing on oncology is projected to experience remarkable expansion in the upcoming years, swelling to an estimated value of $2.27 billion in 2029. This represents a compound annual growth rate (CAGR) of 10.9%. The predicted surge during this forecast period is the result of several factors such as: budding market opportunities, an increased shift towards immuno-oncology treatments, a surge in oncology-specific clinical trials, precision medicine advancements, and targeted therapies. Other notable trends anticipated during the forecasted years involve regenerative medicine and cell therapies, a need for expedited drug development, advancements in digitalization and data analytics, a focus on tumor microenvironments, and an increase in biologics and immunotherapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

What Are The Primary Factors Supporting The Oncology Based In-Vivo CRO Market Expansion?

The rise in cancer cases is anticipated to boost the expansion of the in-vivo CRO market focused on oncology. Cancer encompasses a range of diseases characterized by the uncontrolled multiplication of abnormal cells that exceed their usual limits, originate in nearly any part of the body, and disseminate to other regions via the blood and lymphatic systems. The invention of new drugs and devices for cancer diagnosis and treatment necessitates various preclinical trials, clinical trials, and consistent regulatory oversight before being introduced to the market. An in-vivo oncology-based CRO is a firm engaged by a sponsoring company to offer research services, such as conducting all or some parts of a preclinical in-vivo study (tests involving live entities like animals, plants, or entire cells) before the drug or device is experimented on humans. The surging cancer cases have heightened the need for innovative treatments, propelling the in-vivo CRO market in oncology. For example, in April 2024, the American Cancer Society, a non-profit organization out of the US, reported approximately 609,000 deaths due to cancer and 1.9 million fresh cancer diagnoses in the country in 2022. It is predicted that cancer will cause about 620,000 deaths, indicating a slight rise in death rates in 2024. This increasing incidence of cancer is fuelling the growth of the in-vitro oncology-based CRO market.

Which Segmentation Categories Are Highlighted In The Oncology Based In-Vivo CRO Market Analysis?

The oncology based in-vivo cromarket covered in this report is segmented –

1) By Indication: Blood Cancer; Solid Tumors; Other Indications

2) By Model: Syngeneic Model; Xenograft; Patient Derived Xenograft (PDX); Other Models

3) By Application: Hospitals; Rehabilitation Centers

Subsegments:

1) By Blood Cancer: Leukemia; Lymphoma; Myeloma

2) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Solid Tumors

3) By Other Indications: Neuroblastoma; Germ Cell Tumors; Sarcomas; Other Specific Indications

Which Market Trends Are Expected To Define The Future Of The Oncology Based In-Vivo CRO Market?

In the oncology-focused in vivo CRO market, prominent corporations are prioritizing personalized oncology models in order to stay competitive. These models make use of patient-derived xenografts (PDXs) to develop bespoke treatment plans, thereby improving the relevance and performance of preclinical trials. As an illustration, in 2022, Charles River Laboratories, a life sciences firm based in the U.S., introduced its OncoMouse platform. This platform uses PDX technology for enhanced tumor modeling and is equipped with high-throughput screening features and live monitoring of tumor growth. This enables swift evaluation of therapeutic responses. Furthermore, it offers integrated data analytics for fine-tuning treatment procedures based on each patient’s unique profile. These developments indicate a transition towards more impactful and patient-oriented methods in cancer research.

Which Organizations Are At The Forefront Of The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2025, By The Business Research Company

Oncology Nutrition Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-nutrition-global-market-report

Community Oncology Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Clinical Oncology Next Generation Sequencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model